- Home
- Companies
- luxembourg
- clinical programs
Refine by
Clinical Programs Suppliers Serving Luxembourg
60 companies found
based inRoseville, MINNESOTA (USA)
Rebiotix Inc., a Ferring Company, is a clinical stage biotechnology company founded to revolutionize the treatment of debilitating diseases by harnessing the power of the human microbiome. The company is on the forefront of an exciting potential ...
The human microbiome is defined as the microbial community (bacteria, fungi, viruses and protozoa) present in the human body. The human microbiome aids in the maintenance and development of the immune system and metabolism among other body ...
based inSan Francisco, CALIFORNIA (USA)
Hinge Health is creating a new health care system, built around you. Accessible to 25 million members across 1,250 customers, Hinge Health is the #1 digital clinic for joint and muscle pain, delivering superior member outcomes and proven claims ...
based inRavensburg, GERMANY
Vetter is an international specialist in the production of aseptically prefilled syringe systems, cartridges and vials. We are a family-owned, independent company and do not manufacture our own drugs. Our focus is on providing highly skilled support ...
Explore how we transform your API into a supply of high-quality clinical material for your ...
based inPortsmouth, NEW HAMPSHIRE (USA)
Laborie is a global medical technology company specializing in Gastroenterology, Urology & Urogynecology, and Obstetrics, Gynecology & Neonatal. As we grow our business and expand our product offering, we may move into more medical segments and new ...
based inLaguna Hills, CALIFORNIA (USA)
Adagio Medical, Inc., is a privately held medical device company located in Laguna Hills, California. Co-founded in 2011 by Dr. James Cox, the inventor of “gold standard” Cox-Maze procedure, and Olav Bergheim, a serial entrepreneur, Adagio Medical ...
based inSan Diego, CALIFORNIA (USA)
Resilience is your biomanufacturing innovation partner, leading the pursuit of novel medicines by revolutionizing how they’re made, funded and scaled. The technology of manufacturing complex medicines, like cell and gene therapies, hasn’t kept pace ...
As recombinant protein and monoclonal antibody treatments continue to provide promising pathways for both existing indications and new ones, Resilience has the clinical and commercial experience, expertise and capacity to be your preferred ...
based inPlymouth Meeting, PENNSYLVANIA (USA)
INOVIO is a biotechnology company committed to powering a new way forward in DNA medicines to save and protect lives worldwide. The company is focused on rapidly bringing to market precisely designed and delivered DNA medicines to potentially treat ...
based inCambridge, UNITED KINGDOM
GW is the global leader in developing cannabinoid-based medicines. GW has been researching cannabinoids since 1998 and has established a world leading position in the development of plant-derived cannabinoid therapeutics. GW has established a world ...
GW is committed to developing new medicines to treat rare, treatment-resistant epilepsy conditions where there are limited or in some cases, no approved treatment ...
based inShanghai, CHINA
Elpiscience is a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide. Elpiscience has a robust pipeline of globally innovative cancer immunotherapies covering a wide ...
based inKawaguchi City, Saitama, JAPAN
Since our founding in 1916, alongside its own research and development, ITO has sought out and adopted technologies from around the world to design numerous physiotherapy devices. Drawing on this legacy, we launched full-fledged international ...
High-end Combination Unit with 5 Independent Channels and Body Diagram ...
based inBothell, WASHINGTON (USA)
Cerevast Medical, Inc. is a clinical-stage medical device company based in Bothell, Washington, USA. Leveraging our core expertise in the fields of ultrasound and microsphere technologies, we are committed to developing novel, first-in-class ...
based inFremont, CALIFORNIA (USA)
AlterG develops trusted, leading-edge rehab and training equipment using NASA Differential Air Pressure technology. Our Anti-Gravity Treadmill™ technology empowers people to move in new ways and without pain – to recover mobility, improve wellness, ...
Remove barriers for your patients and advance your clinic with the AlterG® Anti-Gravity Treadmill™ system for physical therapy and rehabilitation. Leading the way in Anti-Gravity Treadmill™ technology since 2005, AlterG® uses ...
based inSchlieren, SWITZERLAND
We are an innovative, Swiss life-science Company aiming to provide patients that suffer from large and deep skin defects with the first automate-produced, personalized skin tissue therapy, denovoSkin“ a safe, effective and accessible therapy for ...
Every year, major burns or a large skin graft have a huge impact on the lives of millions of patients, children and their loved ones. In fact, the standard of care is scarce and still leads to frequent scarring. CUTISS AG wants to offer the best ...
based inIrvine, CALIFORNIA (USA)
Konan Medical develops and distributes innovative ophthalmic diagnostic devices that help clinicians diagnose and manage vision- threatening or potentially life-threatening disorders. Konan Medical USA is an ISO 13485, FDA Registered, MDSAP ...
based inBrunswick, AUSTRALIA
Avania is an integrated global, full-service CRO with specialized expertise in medical device, novel technology, and combination products. They advance products from feasibility all the way through post-approval trials in analytics, clinical trials, ...
Your clinical trial success depends upon the quality and integrity of the data you collect. Avania provides customized data management systems to meet the specific needs of your study. Make better business decisions through easy access to real-time ...
based inBoca Raton, FLORIDA (USA)
Entero Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing targeted, orally delivered therapies for gastrointestinal (GI) diseases. At the core of its research are three proprietary technologies. Latiglutenase is an ...
Latiglutenase, known as IMGX003, is an orally administered formulation comprising two recombinant proteases specifically targeting gluten proteins. It works by breaking down these proteins into smaller, non-reactive fragments, offering an adjunctive ...
based inElkridge, MARYLAND (USA)
Latham BioPharm Group (LBG) is a leading life sciences consulting company that works with pharmaceutical, biotech, CROs, academia, and medical device/diagnostic companies alike to solve complex business, regulatory, and product development ...
Moving products into clinical development is a key milestone that not only creates organizational value, but, more importantly, advances them closer towards commercialization, where they can serve the patients who need them the most. Once in the ...
based inCambridge, MASSACHUSETTS (USA)
Seres Therapeutics is a late-clinical stage biotechnology company with a strong development pipeline and rigorous scientific underpinning, working to revolutionize treatment of a wide range of diseases by modulating the function of the human ...
SER-287 is an investigational, oral, biologically-derived microbiome therapeutic for the treatment of ulcerative colitis (UC). SER-287 is a consortium of multiple bacterial spores manufactured by fractionating and purifying targeted bacteria from ...
based inMartinsried, GERMANY
Proteros is a Munich-based provider of structure-based early stage drug discovery services with a cutting-edge discovery engine tailored to unlock even the most technically challenging drug targets. Proteros supports its clients to reach the right ...
based inCoral Gables, FLORIDA (USA)
We are a late-stage biotech company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making a difference in the lives of patients and their ...
Novel MOA: REL-1017 works as an NMDAR channel blocker with preferential activity at hyperactive GluN1-GluN2D channels. REL-1017 is a novel N-methyl-D-aspartate receptor (NMDAR) channel blocker in phase 3 clinical trials for the treatment of Major ...